April 27, 2015
Eisai announced on April 24 that its Mexican pharmaceutical sales subsidiary has launched the anticancer agents Halaven (eribulin) and Gliadel (carmustine implant) in the country. These products will be the first products to be exclusively marketed by the Eisai group...read more